Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001867899Filer CCCXXXXXXXIs this a LIVE or TEST Filing?IVE TESTSubmission Contact InformationIVE

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc		
SEC File Number	001-38492		
Address of Issuer	23 OLD BOND STREET, FLOOR 3 LONDON UNITED KINGDOM WIS 4PZ		
Phone	7814319100		
Name of Person for Whose Account the Securities are To Be Sold	Tessari Eben		
See the definition of "manager" in non-graph (a) of Dala 144. Informati	the factor has a stand and the stand of the management of the standard st		

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	17000	456789.00	40608972	10/15/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Name of Person Is Date you Nature of Date Amount of Date of Nature of Class Acquired Acquisition from Whom Donor Payment * this Securities Payment Transaction Acquired Acquired Acquired

		Gift?		
Class A Ordinary Shares	10/15/2024 Employee Stock Option Exercise	Kiniksa Pharmaceuticals, 🔲 Ltd.	10000	Broker Payment 10/15/2024 for Cashless Exercise
Class A Ordinary Shares	09/16/2015 Founders Shares	Kiniksa Pharmaceuticals, 🔲 Ltd	7000	09/16/2015 NA

a Cico

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/27/2024	17500	470904.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	09/23/2024	17500	437258.00

144: Remarks and Signature

Remarks	
Date of Notice	10/15/2024
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	04/29/2024
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Eben Tessari

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)